Orbicular’s Ozempic generic gets U.S. FDA tentative nod

What Happened

Hyderabad-based Orbicular Pharmaceutical Technologies and Florida's Apotex Corp. have received tentative FDA approval for a generic version of Ozempic (semaglutide injection). Apotex will market and commercialize the product in the United States as the ANDA applicant. Orbicular specializes in complex peptide-based generics development.

Key Entities

AI Tools